Just can’t get enough
The dawn of the 1980s represented a much more optimistic future than what it eventually turned out to be – will we see the same trend evolve with the seemingly myriad of attempts to box in certain cancer targets?
In some ways this has turned into a bit of a fishing expedition in several ways:
- Uncovering mechanisms of resistance
- Finding rational combinations with a decent therapeutic window
- Developing next generation agents to address the limitations of the earlier versions
If we want to see success in the clinic then what might this look like in the next round of trials and who are the companies active in developing them?
It turns out there are a few surprises in store…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers